



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts**

**Public declaration of interests**

**I, Joseph Emmerich**

**Organisation/Company:** French National Agency for Medicines and Health Products Safety

**Country:** France

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2009-12/2011	BAYER	Rivaroxaban (Xarelto*)	Anticoagulation in the treatment of venous thrombosis
04/2010-12/2011	Boehringer-Ingelheim	Dabigatran (Pradaxa)	Anticoagulation in the treatment of venous thrombosis
05/2011-06/2011	Collatogene	One meeting on cell therapy of PAD	
09/2010-12/2010	LEO	Tinzaparine (Innohep)	Anticoagulation in the treatment of venous thrombosis
01/2009-12/2011	Astra-Zeneca	Board of experts on antithrombotic drugs	

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

## 2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
01/2007-12/2011	BMS	Apixaban (National PI for France in the ADOPT trial)	Prevention of venous thrombosis in medical patient

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2007-12/2011	BAYER	Rivaroxaban	Anticoagulation in venous thrombosis (DVT and PE) - EINSTEIN study
01/2008-12/2011	SCHERING	Varopaxar	PAD

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

In september 2009 I participated to a broadcasting on "Vascular Year 2009" for the American College of Phlebology that was sponsored by Eutherapie.

In november 2011 I participated to a post-university teaching in France on atherosclerosis and lipids sponsored by BMS

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

**"EMA Activities"** encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

**"Confidential Information"** means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

**"Confidential Documents"** mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby

undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

<b>Full Name:</b>	EMMERICH Joseph	25/01/2019
<b>Date:</b>	2019-01-25	

*For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template*